MARIANGELA DE OLIVEIRA SILVA

Dr. MARIANGELA DE OLIVEIRA SILVA

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
JSJamile Ramos da Silva
Jamile Ramos da Silva
KRKarine Bitencourt Rodrigues
Karine Bitencourt Rodrigues
GPGuilherme Formoso Pelegrin
Guilherme Formoso Pelegrin
NSNatiely Silva Sales
Natiely Silva Sales
HMHIROMI MURAMATSU
HIROMI MURAMATSU
LFLuís Ferreira
Luís Ferreira
As mRNA vaccines have proved to be very successful in battling the coronavirus disease 2019 (COVID-19) pandemic, this new modality has attracted widespread interest for the development of potent vaccines against other infectious diseases and cancer. Cervical cancer caused by persistent human papillomavirus (HPV) infection is a major cause of cancer-related deaths in women, and the development of safe and effective therapeutic strategies is urgently needed. In the present study, we compared the performance of three different mRNA vaccine modalities to target tumors associated with HPV-16 infection in mice. We generated lipid nanoparticle (LNP)–encapsulated self-amplifying mRNA as well as unmodified and nucleoside-modified non-replicating mRNA vaccines encoding a chimeric protein derived from the fusion of the HPV-16 E7 oncoprotein and the herpes simplex virus type 1 glycoprotein D (gDE7). We demonstrated that single low-dose immunizations with any of the three gDE7 mRNA vaccines induced activation of E7-specific CD8 + T cells, generated memory T cell responses capable of preventing tumor relapses, and eradicated subcutaneous tumors at different growth stages. In addition, the gDE7 mRNA-LNP vaccines induced potent tumor protection in two different orthotopic mouse tumor models after administration of a single vaccine dose. Last, comparative studies demonstrated that all three gDE7 mRNA-LNP vaccines proved to be superior to gDE7 DNA and gDE7 recombinant protein vaccines. Collectively, we demonstrated the immunogenicity and therapeutic efficacy of three different mRNA vaccines in extensive comparative experiments. Our data support further evaluation of these mRNA vaccines in clinical trials.

1 January 2021 in International Journal of Biological Sciences
Verified
Journal Article
Open access
MSMARIANGELA DE OLIVEIRA SILVA
MARIANGELA DE OLIVEIRA SILVA
BABianca S. Almeida
Bianca S. Almeida
NSNatiely S. Sales
Natiely S. Sales
MDMariana O. Diniz
Mariana O. Diniz
LALuana Raposo de Melo Moraes Aps
Luana Raposo de Melo Moraes Aps
LFLuís Ferreira
Luís Ferreira
The generation of successful anticancer vaccines relies on the ability to induce efficient and long-lasting immune responses to tumor antigens. In this scenario, dendritic cells (DCs) are essential cellular components in the generation of antitumor immune responses. Thus, delivery of tumor antigens to specific DC populations represents a promising approach to enhance the efficiency of antitumor immunotherapies. In the present study, we employed antibody-antigen conjugates targeting a specific DC C-type lectin receptor. For that purpose, we genetically fused the anti-DEC205 monoclonal antibody to the type 16 human papillomavirus (HPV-16) E7 oncoprotein to create a therapeutic vaccine to treat HPV-associated tumors in syngeneic mouse tumor models. The therapeutic efficacy of the αDEC205-E7 mAb was investigated in three distinct anatomical tumor models (subcutaneous, lingual and intravaginal). The immunization regimen comprised two doses of the αDEC205-E7 mAb coadministered with a DC maturation stimulus (Polyinosinic:polycytidylic acid, poly (I:C)) as an adjuvant. The combined immunotherapy produced robust antitumor effects on both the subcutaneous and orthotopic tumor models, stimulating rapid tumor regression and long-term survival. These outcomes were related to the activation of tumor antigen-specific CD8+ T cells in both systemic compartments and lymphoid tissues. The αDEC205-E7 antibody plus poly (I:C) administration induced long-lasting immunity and controlled tumor relapses. Our results highlight that the delivery of HPV tumor antigens to DCs, particularly via the DEC205 surface receptor, is a promising therapeutic approach, providing new opportunities for the development of alternative immunotherapies for patients with HPV-associated tumors at different anatomical sites.

6 February 2024 in ACS Applied Nano Materials
Verified
Journal Article
Open access
GDGiovanne Delechiave
Giovanne Delechiave
MSMARIANGELA DE OLIVEIRA SILVA
MARIANGELA DE OLIVEIRA SILVA
MAMaria Fernanda Castro Amarante
Maria Fernanda Castro Amarante
Denisse Mallaupoma CamarenaDenisse Mallaupoma Camarena
Denisse Mallaupoma Camarena
AVAlexia Adrianne Venceslau-Carvalho
Alexia Adrianne Venceslau-Carvalho
Luiz CatalaniLuiz Catalani
Luiz Catalani

6 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MFMarcilio Fumagalli
Marcilio Fumagalli
AKAnna Kaczynska
Anna Kaczynska
MAMarius Allombert
Marius Allombert
ÁLÁgata Lopes-Ribeiro
Ágata Lopes-Ribeiro
MSMARIANGELA DE OLIVEIRA SILVA
MARIANGELA DE OLIVEIRA SILVA
MNMichel C. Nussenzweig
Michel C. Nussenzweig
RIO is an ongoing double blind randomized placebo controlled human trial in which participants that started antiretroviral therapy (ART) during primary or early-stage infection underwent treatment interruption and were randomly assigned to a group receiving one or two doses of two long acting broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS (Arm A), or saline (Arm B). The two arms differed significantly in time to viral rebound, ART restart and number of individuals that remained off therapy after 96 weeks (p=0.001) 1. Here we report on the relationship between viremic control, the latent HIV-1 proviral reservoir, rebound viruses and their sensitivity to the infused and autologous antibodies. Pre-infusion reservoir measurements showed low levels of intact proviral HIV-1 DNA in circulating CD4+ T cells in both arms. The rebounding viruses in participants that received the antibodies, showed significant selection for resistance to 10-1074-LS but not to 3BNC117-LS. Notably, there was a significant correlation between initial reservoir sensitivity to autologous antibodies and to 10-1074 and time to rebound. Finally, comparison of pre-infusion and pre-rebound HIV-1 proviral reservoir in participants that received antibodies showed that the reservoir of intact proviruses decayed faster than earlier reports with a half-life of 0.65 years.

16 September 2023 in Viruses
Verified
Journal Article
Open access
PDF file
SPSamuel Santos Pereira
Samuel Santos Pereira
RARobert Andreata-Santos
Robert Andreata-Santos
MAMaria Fernanda Castro Amarante
Maria Fernanda Castro Amarante
AVAlexia Adrianne Venceslau-Carvalho
Alexia Adrianne Venceslau-Carvalho
NSNatiely Silva Sales
Natiely Silva Sales
LFLuís Ferreira
Luís Ferreira
Dengue is an infectious disease of global health concern that continues to require surveillance. Serological testing has been used to investigate dengue-infected patients, but specificity is affected by the co-circulation of ZIKA virus (ZIKV), which shares extensive antigen similarities. The goal of this study was the development of a specific dengue virus (DENV) IgG ELISA based on a multi-epitope NS1-based antigen for antibody detection. The multi-epitope protein (T-ΔNS1), derived from a fragment of the NS1-protein of the four DENV serotypes, was expressed in Escherichia coli and purified via affinity chromatography. The antigenicity and specificity were evaluated with sera of mice infected with DENV-1–4 or ZIKV or after immunization with the recombinant ΔNS1 proteins. The performance of the T-ΔNS1-based IgG ELISA was also determined with human serum samples. The results demonstrate that the DENV T-ΔNS1 was specifically recognized by the serum IgG of dengue-infected mice or humans but showed no or reduced reactivity with ZIKV-infected subjects. Based on the available set of clinical samples, the ELISA based on the DENV T-ΔNS1 achieved 77.42% sensitivity and 88.57% specificity. The results indicate that the T-ΔNS1 antigen is a promising candidate for the development of specific serological analysis.

27 March 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
MSMARIANGELA DE OLIVEIRA SILVA
MARIANGELA DE OLIVEIRA SILVA
MAMaria Fernanda Castro Amarante
Maria Fernanda Castro Amarante
AVAlexia Adrianne Venceslau-Carvalho
Alexia Adrianne Venceslau-Carvalho
BABianca Da Silva Almeida
Bianca Da Silva Almeida
IDIsabela Pazotti Daher
Isabela Pazotti Daher
SBSilvia Beatriz Boscardin
Silvia Beatriz Boscardin
The unprecedented global impact caused by SARS-CoV-2 imposed huge health and economic challenges, highlighting the urgent need for safe and effective vaccines. The receptor-binding domain (RBD) of SARS-CoV-2 is the major target for neutralizing antibodies and for vaccine formulations. Nonetheless, the low immunogenicity of the RBD requires the use of alternative strategies to enhance its immunological properties. Here, we evaluated the use of a subunit vaccine antigen generated after the genetic fusing of the RBD with a mouse IgG antibody. Subcutaneous administration of RBD-IgG led to the extended presence of the protein in the blood of immunized animals and enhanced RBD-specific IgG titers. Furthermore, RBD-IgG immunized mice elicited increased virus neutralizing antibody titers, measured both with pseudoviruses and with live original (Wuhan) SARS-CoV-2. Immunized K18-hACE2 mice were fully resistant to the lethal challenge of the Wuhan SARS-CoV-2, demonstrated by the control of body-weight loss and virus loads in their lungs and brains. Thus, we conclude that the genetic fusion of the RBD with an IgG molecule enhanced the immunogenicity of the antigen and the generation of virus-neutralizing antibodies, supporting the use of IgG chimeric antigens as an approach to improve the performance of SARS-CoV-2 subunit vaccines.